Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.

We assessed the short and long-term efficacy and safety of the lipid lowering drugs, nicotinic acid, and the HMG-CoA reductase inhibitor, lovastatin, in combination with cholestyramine in four renal transplant patients. Combination therapy with cholestyramine failed to lower the TC and LDL to the levels recommended by the NCEP guidelines.